Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region
- 26 July 2017
- journal article
- research article
- Published by Springer Nature in Medical Oncology
- Vol. 34 (9) , 149
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based studyOncoTargets and Therapy, 2017
- Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients with CancerCancer Control, 2016
- Cabozantinib versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World PracticeJournal of Oncology Practice, 2015
- Cartographic Mapping and Travel Burden to Assess and Develop Strategies to Improve Minority Access to National Cancer Clinical TrialsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Overall Survival in Renal-Cell Carcinoma with Pazopanib versus SunitinibNew England Journal of Medicine, 2014
- Contemporary management of renal cell carcinoma ( RCC ) in V ictoria: implications for longer term outcomes and costsBJU International, 2013
- Access to Cancer Services for Rural Colorectal Cancer PatientsThe Journal of Rural Health, 2008
- Barriers to recruiting underrepresented populations to cancer clinical trials: A systematic reviewCancer, 2007